Acta Neuropathologica

, Volume 114, Issue 4, pp 425–430 | Cite as

Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report

  • Hideaki Yokoo
  • Yoichi Nakazato
  • Yasuo Harigaya
  • Natsu Sasaki
  • Yukifusa Igeta
  • Hideaki Itoh
Case Report

Abstract

The authors describe a 68-year-old female who developed a rapidly progressing leukoencephalopathy involving the cerebrum and brain stem. The disease appeared during low-dose oral methotrexate (MTX) therapy for rheumatoid arthritis. An extensive clinical investigation discounted other possible causes of white matter lesions. Autopsy identified an uninterrupted severe demyelinating, partially liquefactive necrosis-like lesion in the white matter accompanied by astrogliosis and occasional swollen axons therein. The lesion was generally symmetrical, and distributed throughout the whole cerebral white matter except for the bilateral temporal lobes and the rostral part of the frontal lobes. The internal capsules and cerebral peduncles were spongy, and the central and lateral parts of the pons, especially the transverse cerebellopontine tracts, were affected similarly. It was of note that the lesion was accompanied by neither vascular diseases nor lymphocyte infiltration. Thus, the pathological findings were similar to those of a severe form of central and extrapontine myelinolysis, and clearly different from ordinary MTX leukoencephalopathy reported in patients receiving intrathecal or intravenous MTX therapy, known as “disseminated necrotizing leukoencephalopathy”. Another possibility is that synergistic effects of several white-matter-damaging disorders may have contributed to the hitherto unknown lesion. To our knowledge, this is the first autopsy record that describes an oral MTX-associated neurological disorder.

Keywords

Leukoencephalopathy Demyelination Rheumatoid arthritis Methotrexate Autopsy 

References

  1. 1.
    Adams RD, Victor M, Mancall EL (1959) Central pontine myelinolysis: a hitherto undescribed disease occurring in alcoholic and malnourished patients. AMA Arch Neurol Psychiatry 81:154–172PubMedGoogle Scholar
  2. 2.
    Bleyer WA, Drake JC. Chabner BA (1973) Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukaemia. N Eng J Med 289:770–773CrossRefGoogle Scholar
  3. 3.
    Groff GD, Shenberger KN, Wilke WS, Taylor TH (1983) Low dose oral methotrexate in rheumatoid arthritis: an uncontrolled trial and review of the literature. Semin Arthritis Rheum 12:333–347PubMedCrossRefGoogle Scholar
  4. 4.
    Hoffmeister RT (1983) Methotrexate therapy for rheumatoid arthritis: 15 years’ experience. Am J Med 75(Suppl 6A):69–73PubMedCrossRefGoogle Scholar
  5. 5.
    Kay HE, Knapton PJ, O’Sullivan JP, Wells DG, Harris RF, Innes EM, Stuart J, Schwartz FC, Thompson EN (1972) Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child 47:344–354PubMedCrossRefGoogle Scholar
  6. 6.
    Kleinschmidt-Demasters BK, Rojiani AM, Filley CM (2006) Central and extrapontine myelinolysis: then and now. J Neuropathol Exp Neurol 65:1–11PubMedGoogle Scholar
  7. 7.
    Kremer JM, Lee JK (1986) The safety and efficacy of the use of methotrexate in long-term therapy in rheumatoid artiritis. Arthritis Rheum 29:822–831PubMedCrossRefGoogle Scholar
  8. 8.
    Lampl C, Yazdi K (2002) Central pontine myelinolysis. Eur Neurol 47:3–10PubMedCrossRefGoogle Scholar
  9. 9.
    Linnebank M, Pels H, Kleczar N, Farmand S, Fliessbach K, Urbach H, Orlopp K, Klockgether T, Schmidt-Wolf IG, Schlegel U (2005) MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology 64:912–913PubMedGoogle Scholar
  10. 10.
    Meadows AT, Evans AE (1976) Effects of chemotherapy on the central nervous system: a study parenteral methotrexate in long-term survivors of leukemia and lymphoma in childhood. Cancer 37:1079–1085PubMedCrossRefGoogle Scholar
  11. 11.
    Nakazato Y, Ishida Y, Morimatsu M (1980) Disseminated necrotizing leukoencephalopathy. Acta Pathol Jpn 30:659–670PubMedGoogle Scholar
  12. 12.
    Nakazato Y, Ishizeki J, Takahashi K, Yamaguchi H, Kamei T, Mori T (1982) Localization of S-100 protein and glial fibrillary acidic protein-related antigen in pleomorphic adenoma of the salivary glands. Lab Invest 46:621–626PubMedGoogle Scholar
  13. 13.
    Nakazato Y, Sasaki A, Hirato J, Ishida Y (1987) Monoclonal antibodies which recognize phosphorylated and nonphosphorylated epitopes of neurofilament protein. Biomed Res 8:369–376Google Scholar
  14. 14.
    Price RA, Jamieson PA (1975) The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 35:306–318PubMedCrossRefGoogle Scholar
  15. 15.
    Price RA, Birdwell DA (1978) The central nervous system in childhood leukemia. III. Mineralizing microangiopathy and dystrophic calcification. Cancer 42:717–728PubMedCrossRefGoogle Scholar
  16. 16.
    Prineas JW, McDonald WI, Franklin RJM (2002) Demyelinating diseases. In: Graham DI, Lantos PL (eds) Greenfield’s neuropathology, 7th edn. Arnold, London, pp 471–550Google Scholar
  17. 17.
    Ramaekers VT, Reul J, Kusenbach G, Thron A, Heimann G (1997) Central pontine myelinolysis associated with acquired folate depletion. Neuropediatrics 28:126–130PubMedCrossRefGoogle Scholar
  18. 18.
    Rubinstein LJ, Herman MM, Long TF, Wilbur JR (1975) Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 35:291–305PubMedCrossRefGoogle Scholar
  19. 19.
    Steinsson K, Weinstein A, Korn J, Abeles M (1982) Low dose methotrexate in rheumatoid arthritis. J Rheumatol 9:860–866PubMedGoogle Scholar
  20. 20.
    van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB (2001) Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 44:1515–1524PubMedCrossRefGoogle Scholar
  21. 21.
    Weinblatt ME (1985) Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 12(Suppl 12):35–39Google Scholar
  22. 22.
    Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE (1985) Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818–822PubMedCrossRefGoogle Scholar
  23. 23.
    Weiss HD, Walker MD, Wiernik PH (1974) Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med 291:75–81PubMedCrossRefGoogle Scholar
  24. 24.
    Wernick R, Smith DL (1989) Central nervous system toxicity associated with weekly low dose methotrexate treatment. Arthritis Rheum 32:770–775PubMedCrossRefGoogle Scholar
  25. 25.
    Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ (2006) Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54:1087–1095PubMedCrossRefGoogle Scholar
  26. 26.
    Willkens RF, Watson MA, Paxson CS (1980) Low dose pulse methotrexate therapy in rheumatoid arthritis. J Rheumatol 7:501–505PubMedGoogle Scholar
  27. 27.
    Worthley SG, McNeil JD (1996) Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis. J Rheumatol 22:335–337Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Hideaki Yokoo
    • 1
  • Yoichi Nakazato
    • 1
  • Yasuo Harigaya
    • 2
  • Natsu Sasaki
    • 2
  • Yukifusa Igeta
    • 2
  • Hideaki Itoh
    • 3
  1. 1.Department of Human PathologyGunma University Graduate School of MedicineMaebashi, GunmaJapan
  2. 2.Department of NeurologyMaebashi Red-Cross HospitalMaebashiJapan
  3. 3.Department of PathologyMaebashi Red-Cross HospitalMaebashiJapan

Personalised recommendations